Alexandre Mérieux Assumes Role of bioMérieux CEO

Regulatory News:

Alexandre Mérieux will take on the role of Chief Executive Officer of bioMérieux (Paris:BIM) and head its Management Committee. To step up the rollout of its strategic plan, a new organization is being deployed.

The Management Committee, led by Alexandre Mérieux, is in charge of implementing the strategy decided by bioMérieux’s Board of Directors, which remains chaired by Jean-Luc Belingard. The Committee’s main missions are to define the priority action and development areas, oversee strategic projects and allocate the necessary resources to the different departments within the Group.

Evolution of the operational organization

To continue bioMérieux’s international development and always better serve customers, three regional organizations with expanded responsibilities have been created: a Europe-Middle East-Africa region, an Americas region and an Asia-Pacific region. In parallel, two business units for bioMérieux’s customer segments, a Clinical Unit and an Industry Unit, have been established.

The Business Development, Molecular Biology and Quality departments will report to Jean-Luc Belingard. All other departments, including Investor Relations, will report to Alexandre Mérieux.

Jean-Luc Belingard, Chairman, stated: "I am very pleased to see Alexandre Mérieux take on the role of CEO. In the past three years, we have made major acquisitions and business agreements that hold exciting prospects for our Company. We will work with Alexandre to bring them to fruition with a shared humanist and long-term vision”.

Alexandre Mérieux, Chief Executive Officer, adds: "My new role is an extension of our family’s commitment to bioMérieux’s development. I will be able to count on Jean-Luc Belingard’s support, an outstanding Board and teams I know well and who have, time and time again, demonstrated their dedication to serving biologists and patients”.

ABOUT BIOMERIEUX

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for 50 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors. In 2013, revenues reached €1,588 million with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).
Corporate website: www.biomerieux.com. Investor website: www.biomerieux-finance.com.